August 14, 2025 — Leads & Copy — Enveric Biosciences (NASDAQ: ENVB) announced its financial results for the second quarter ended June 30, 2025, and provided a business update, highlighting progress with its lead drug candidate, EB-003.
According to Enveric, EB-003 engages both the 5-HT₂A and 5-HT₁B receptors through a dual mechanism of action, forming the foundation for a novel pharmacological class. The company has made progress in expanding its intellectual property portfolio, securing an additional patent grant in its EVM-301 portfolio and patent allowances across multiple distinct chemical classes in its EVM-301 and EVM-401 portfolios.
The company expects to file an Investigational New Drug (IND) application for EB-003 and prepare for its first-in-human study. Net loss attributable to common stockholders was $2.5 million for the quarter ending June 30, 2025, or $0.97 per share.
Joseph Tucker, Ph.D., Director and CEO of Enveric, stated that the second quarter of 2025 represented a period of focused execution across all key areas of the business, most notably with the advancement of EB-003.
Contact:
ir@enveric.com
Source: Enveric Biosciences
